Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Chromocell Therapeutics Corporation (CHRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: CHRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 83.33% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.90M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 4.50 - 38.00 | Updated Date 07/4/2025 |
52 Weeks Range 4.50 - 38.00 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -188.95% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13047474 | Price to Sales(TTM) - |
Enterprise Value 13047474 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.58 | Shares Outstanding 6595850 | Shares Floating 2561300 |
Shares Outstanding 6595850 | Shares Floating 2561300 | ||
Percent Insiders 53.87 | Percent Institutions 13.6 |
Upturn AI SWOT
Chromocell Therapeutics Corporation
Company Overview
History and Background
Chromocell Therapeutics Corporation is a biopharmaceutical company focusing on the discovery and development of novel therapeutics. It was founded in 2002. A key milestone was the development of its Chromovertu00ae technology, enabling the creation of cell-based assays for drug discovery. Over time, Chromocell has shifted its focus towards developing non-addictive pain therapeutics and flavor enhancers.
Core Business Areas
- Drug Discovery and Development: Chromocell focuses on discovering and developing novel therapeutics, particularly in the area of pain management. It leverages its Chromovertu00ae technology for high-throughput screening and target identification.
- Flavor and Scent Ingredient Discovery: Chromocell also develops and commercializes flavor and scent ingredients using its proprietary technology platform. This includes identifying and creating novel flavor compounds for the food and beverage industry.
Leadership and Structure
Chromocell Therapeutics Corporation is a privately held company and has a Board of Directors that guides the CEO and executive team. Detailed organizational information and leadership structure are not publicly available.
Top Products and Market Share
Key Offerings
- CC846: A non-opioid pain therapeutic for chronic pain. Market share data is not publicly available as CC846 is currently in clinical development. Key competitors in the pain management market include companies developing opioids and non-opioid pain relievers, such as Pfizer (PFE) and Eli Lilly (LLY).
- Flavor Ingredients: Novel flavor ingredients for the food and beverage industry. Market share data is not publicly available due to the proprietary nature of Chromocell's flavor compounds. Competitors include flavor houses such as Givaudan (GVDNY) and International Flavors & Fragrances (IFF).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. The flavor and fragrance industry is driven by consumer demand for innovative and appealing flavors and scents.
Positioning
Chromocell is positioned as an innovator in both the biopharmaceutical and flavor/fragrance industries. Its Chromovertu00ae technology gives it a competitive advantage in identifying novel drug targets and flavor compounds. They are a niche player compared to larger market incumbents.
Total Addressable Market (TAM)
The pain management market is estimated to be worth billions of dollars, with the global flavor and fragrance market also worth billions. Chromocell is positioned to capture a share of these markets through its innovative products. TAM estimates depend on the success of CC846 and commercialization of flavor ingredients. Estimates are often found in market reports which require paid subscriptions.
Upturn SWOT Analysis
Strengths
- Proprietary Chromovertu00ae technology
- Focus on non-opioid pain therapeutics
- Innovation in flavor and fragrance discovery
- Experienced scientific team
Weaknesses
- Limited financial resources as a private company
- Reliance on clinical trial success for drug development
- Dependence on strategic partnerships for commercialization
- Lack of publicly available data hinders full analysis
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Growth in the flavor and fragrance market
- Increased demand for non-addictive pain relievers
Threats
- Regulatory hurdles for drug approval
- Competition from established pharmaceutical companies
- Patent challenges
- Changes in consumer preferences in the flavor market
Competitors and Market Share
Key Competitors
- PFE
- LLY
- IFF
- GVDNY
Competitive Landscape
Chromocell's competitive advantage lies in its proprietary technology platform. However, it faces significant competition from larger, well-established companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not publicly available.
Future Projections: Future growth projections are not publicly available, as the company is private. Analyst estimates are not available.
Recent Initiatives: Recent initiatives include continued clinical development of CC846 and expansion of its flavor ingredient portfolio.
Summary
Chromocell Therapeutics Corporation is a private company focused on innovative drug discovery and flavor ingredient development. Its proprietary technology offers a competitive advantage, but the company faces financial limitations and competition from larger players. Success hinges on clinical trial outcomes and strategic partnerships, but without public data, a full assessment is impossible. The company needs to secure adequate funding and navigate the complex regulatory environment for drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Press releases
Disclaimers:
Data is based on publicly available information and may be incomplete. Market share estimates are approximate. This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Chromocell Therapeutics Corporation
Exchange NYSE MKT | Headquaters Freehold, NJ, United States | ||
IPO Launch date 2024-02-16 | President, CEO, CFO, Treasurer, Secretary & Director Mr. Francis Knuettel II, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://channeltherapeutics.com |
Full time employees 4 | Website https://channeltherapeutics.com | ||
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both acute and chronic eye pain; and CT3000 to treat post operative pain with the use of nerve blocks. The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024. Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.